Table 4.

Number of incident events for each outcome and person years of exposure to mutually exclusive treatment groups

Variables	Heart failure			Cardiovascular disease			All cause mortality
	No of cases	Person years		No of cases	Person years		No of cases	Person years
Periods with no treatment	5317	675 598		9769	541 445		27 367	707 183
Monotherapy:
Metformin	3334	570 230		7376	464 698		9815	589 353
Sulphonylureas	1211	82 466		1752	59 918		5654	90 846
Insulin	220	14 802		290	11 408		1349	16 859
Glitazones	9	1671		24	1352		48	1704
Gliptins	23	2361		43	1874		112	2560
Other diabetes drugs	18	1474		31	1168		72	1618
Dual treatment:
Metformin and sulphonylureas	2439	304 023		4772	242 136		5350	316 576
Metformin and insulin	189	17 328		262	13 153		399	18 540
Metformin and glitazones	75	17 825		160	15 742		163	18 024
Metformin and gliptins	114	23 530		263	19 898		257	24 218
Metformin and other diabetes drugs	60	9009		119	7,479		85	9375
Sulphonylureas and insulin	94	3756		100	2558		369	4593
Sulphonylureas and glitazones	37	3444		59	2691		114	3564
Sulphonylureas and gliptins	47	4068		71	2988		164	4451
Sulphonylureas and other diabetes drugs	21	973		22	765		46	1096
Triple treatment:
Metformin, sulphonylureas, and insulin	123	10 893		212	8209		283	11 593
Metformin, sulphonylureas, and glitazones	133	24 790		344	21 295		209	25 168
Metformin, sulphonylureas, and gliptins	181	30 617		412	24 885		355	31 762
Metformin, sulphonylureas, and other	60	9636		127	7902		87	10 070
All other drug combinations	101	13 519		226	11 160		178	14 127
Total	13 806	1 822 013		26 434	1 462 724		52 476	1 903 280